plus sign inside this box + INFORMATION DISCLOSURE

Cite

No.1

Examiner

Initials*

PTO/SB/08A(05/03) Approved for use through 05/31/2003, OMB 0651-0031 **Application Number** 10/618,336 Filing Date

Attorney Docket Number

July 11, 2003 First Named Inventor Ferrone et al. Art Unit 1646 Examiner Name

03551.0135

STATEMENT BY APPLICANT (Use as many sheets as necessary)

Document Number

Sheet

US-5,807,978

US-5,882,654

US-US-US-US-US-

U.S. PATENT DOCUMENTS Pages, Columns, Lines **Publication Date** Name of Patentee or Where Relevant Number-Kind Code 2 (if known) MM-DD-YYYY Applicant of Cited Document Passages or Relevant Figures Appear 09-15-1998 Kokolus et al. 03-16-1999 Morton

US-US-US-US-US-US-US-US-US-US-US-US-

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. 1	Foreign Patent Document	Publication	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear		
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)	Date MM-DD-YYYY			T ⁶	
	<u> </u>	,					
,							
					_		

	/	•		
Examiner Signature	uln MAA	Date Considered	02/25 Rus	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at <u>www.uspto.gov</u> or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.



Please type a plus sign inside this box +

PTO/SB/08B(05/03)

Approved for use through 05/31/2003, OMB 0651-003

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet	2	of	2

		ough 03/31/2003, Olvib 0631-0031
	Application Number	10/618,336
	Filing Date	July 11, 2003 .
	First Named Inventor	Ferrone et al.
	Group Art Unit	1646
İ	Examiner Name	
1	Attorney Docket Number	03551.0135

	NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	.T ²			
Y	1	CHAPMAN ET AL., Vaccination with a Bivalent G _{M2} and G _{D2} Ganglioside Conjugate Vaccine: A Trial Comparing Doses of G _{D2} -Keyhole, Clinical Cancer Research (December 2000) Vol. 6, pp. 4658-4662				
	2	GRANT ET AL., Long Survival of Patients with Small Cell Lung Cancer after Adjuvant Treatment with the Anti-Idiotypic Antibody BEC2 Plus Bacillus Calmette-Guérin, Clinical Cancer Research (June 1999) Vol. 5, pp. 1319-1323				
	3	LESINSKI ET AL., A DNA Vaccine Encoding a Peptide Mimic of Streptococcus Pneumoniae Serotype 4 Capsular Polysaccharide Induces Specific Anti-Carbohydrate Antibodies in Balb/c Mice, Vaccine (2001) Vol. 19, pp. 1717-1726				
	4	LUO ET AL., A Molecular Basis for Functional Peptide Mimicry of a Carbohydrate Antigen, The Journal of Biological Chemistry (May 26, 2000) Vol. 275, No. 21, pp. 16146-16154				
	5	MCCAFFERY ET AL., Immunization of Melanoma Patients with BEC2 Anti-Idiotypic Monoclonal Antibody That Mimics GD3 Ganglioside: Enhanced Immunogenicity WhenCombined with Adjuvant, Clinical Cancer Research (April 1996) Vol. 2, pp. 679-686				
	6	QIU ET AL., Towards the Development of Peptide Mimotopes of Carbohydrate Antigens as Cancer Vaccines, Hybridoma (1999) Vol. 18, No. 1, pp. 103-112				
W	7	YAO ET AL., Immunization of Melanoma Patients with BEC2-Keyhole Limpet Hemocyanin Plus BCG Intradermally Followed by Intravenous Booster Immunizations with BEC2 to Induce Anti-GD3 Ganglioside Antibodies, Clinical Cancer Research (January 1999) Vol. 5, pp. 77-81				

Examiner Signature	Danlander	Date Considered	12/05/ars	
	2 .			

Burden Hour Statement: The form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. Send to the Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number. ² Applicant is to place a check mark here if English Translation is attached.